Aardvark Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	61.64	9.74	15.56
Short-Term Investments	12.02	0.25	0.55
Cash & Short-Term Investments	73.66	9.99	16.11
Cash Growth	637.44%	-37.98%	-
Prepaid Expenses	0.47	0.25	0.32
Other Current Assets	-	0.13	0.07
Total Current Assets	74.14	10.37	16.49
Property, Plant & Equipment	0.74	0.16	0.25
Other Long-Term Assets	2.64	0.01	0.01
Total Assets	77.51	10.54	16.76
Accounts Payable	2.3	1.04	0.26
Accrued Expenses	2.29	0.24	0.24
Current Portion of Leases	0.34	0.11	0.1
Total Current Liabilities	4.93	1.38	0.6
Long-Term Leases	0.44	0.05	0.16
Other Long-Term Liabilities	0.03	0	0.02
Total Liabilities	5.39	1.43	0.78
Additional Paid-In Capital	3.68	2.94	2.61
Retained Earnings	-58.33	-37.74	-30.53
Total Common Equity	-54.64	-34.8	-27.92
Shareholders' Equity	72.11	9.1	15.98
Total Liabilities & Equity	77.51	10.54	16.76
Total Debt	0.78	0.16	0.26
Net Cash (Debt)	72.88	9.83	15.84
Net Cash Growth	641.67%	-37.97%	-
Net Cash Per Share	18.24	2.48	4.07
Filing Date Shares Outstanding	21.7	3.97	3.89
Total Common Shares Outstanding	4.07	3.97	3.89
Working Capital	69.21	8.99	15.9
Book Value Per Share	-13.44	-8.77	-7.18
Tangible Book Value	-54.64	-34.8	-27.92
Tangible Book Value Per Share	-13.44	-8.77	-7.18

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q